Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06103864




Registration number
NCT06103864
Ethics application status
Date submitted
23/10/2023
Date registered
27/10/2023
Date last updated
29/05/2024

Titles & IDs
Public title
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Scientific title
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Secondary ID [1] 0 0
D7630C00001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dato-DXd
Treatment: Drugs - Durvalumab
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Nab-paclitaxel
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Carboplatin
Treatment: Drugs - Pembrolizumab

Experimental: Dato-DXd + durvalumab - Arm 1: Dato-DXd + durvalumab

Active Comparator: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab - Arm 2: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin)

Experimental: Dato-DXd - Arm 3: Dato-DXd


Treatment: Drugs: Dato-DXd
Provided in 100mg vials. IV infusion. Experimental drug.

Treatment: Drugs: Durvalumab
Provided in 500mg vials. IV infusion. Experimental drug.

Treatment: Drugs: Paclitaxel
IV infusion. Active comparator.

Treatment: Drugs: Nab-paclitaxel
IV infusion. Active comparator.

Treatment: Drugs: Gemcitabine
IV infusion. Active comparator.

Treatment: Drugs: Carboplatin
IV infusion. Active comparator.

Treatment: Drugs: Pembrolizumab
IV infusion. Active comparator.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS)
Timepoint [1] 0 0
From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
From randomisation until the date of death due to any cause (anticipated to be up to 64 months).
Secondary outcome [2] 0 0
Objective Response Rate (ORR)
Timepoint [2] 0 0
From randomisation up until progression (anticipated to be up to 33 months).
Secondary outcome [3] 0 0
Duration of Response (DoR)
Timepoint [3] 0 0
From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).
Secondary outcome [4] 0 0
Progression-Free Survival (PFS) by Investigator assessment
Timepoint [4] 0 0
From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).
Secondary outcome [5] 0 0
Clinical Benefit Rate (CBR) at 24 weeks
Timepoint [5] 0 0
From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).
Secondary outcome [6] 0 0
Time to deterioration (TTD) in breast and arm symptoms in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Timepoint [6] 0 0
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Secondary outcome [7] 0 0
Time to deterioration (TTD) in pain in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Timepoint [7] 0 0
Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Secondary outcome [8] 0 0
Time to deterioration (TTD) in physical functioning in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Timepoint [8] 0 0
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Secondary outcome [9] 0 0
Time to deterioration (TTD) in GHS/QoL in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Timepoint [9] 0 0
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Secondary outcome [10] 0 0
Time to First Subsequent Therapy (TFST)
Timepoint [10] 0 0
From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).
Secondary outcome [11] 0 0
Time to Second Subsequent Therapy (TSST)
Timepoint [11] 0 0
From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).
Secondary outcome [12] 0 0
Progression Free Survival 2 (PFS2)
Timepoint [12] 0 0
From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).
Secondary outcome [13] 0 0
Pharmacokinetics of Dato-DXd in combination with durvalumab
Timepoint [13] 0 0
From first dose to end of treatment (anticipated to be up to 33 months).
Secondary outcome [14] 0 0
Immunogenicity of Dato-DXd in combination with durvalumab
Timepoint [14] 0 0
From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
Secondary outcome [15] 0 0
Safety and tolerability of Dato-DXd + durvalumab as compared with ICC + pembrolizumab
Timepoint [15] 0 0
From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).

Eligibility
Key inclusion criteria
Key Inclusion Criteria

- Histologically or cytologically documented locally recurrent inoperable, which cannot
be treated with curative intent, or metastatic TNBC, as defined by the ASCO-CAP
guidelines.

- ECOG PS 0 or 1.

- All participants must provide a FFPE metastatic or locally recurrent inoperable tumour
sample.

- PD-L1 positive TNBC based on results from an appropriately validated investigational
PD-L1 (22C3) assay (CPS = 10) from a sponsor designated central laboratory.

- No prior chemotherapy or targeted systemic anti-cancer therapy for metastatic or
locally recurrent inoperable breast cancer.

- Patients with recurrent disease will be eligible if they have completed treatment
for Stage I-III breast cancer, if indicated, and =6 months have elapsed between
completion of treatment with curative intent and the first documented recurrence.

- Eligible for one of the chemotherapy options listed as ICC (paclitaxel,
nab-paclitaxel, or gemcitabine + carboplatin).

- Measurable disease as per RECIST 1.1.

- Adequate bone marrow reserve and organ function.

- Male and female participants of childbearing potential must agree to use
protocol-specified method(s) of contraception.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

- As judged by investigator, severe or uncontrolled medical conditions including
systemic diseases, history of allogeneic organ transplant and active bleeding
diseases, ongoing or active infection, significant cardiac or psychological
conditions.

- History of another primary malignancy except for malignancy treated with curative
intent with no known active disease within 3 years before Cycle 1 Day 1 and of low
potential risk for recurrence.

- Neoplastic spinal cord compression or active brain metastases, leptomeningeal
carcinomatosis or history of leptomeningeal carcinomatosis.

- Participants with treated clinically inactive brain metastases that are no longer
symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be
included in the study if they have recovered from acute toxic effects of radiotherapy.

- Uncontrolled infection requiring IV antibiotics, antivirals or antifungals.

- Active or uncontrolled hepatitis B or C virus infection.

- Known HIV infection that is not well controlled.

- Uncontrolled or significant cardiac disease.

- History of non-infectious ILD/pneumonitis (including radiation pneumonitis) that
required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot
be ruled out by imaging at screening.

- Severe pulmonary function compromise.

- Clinically significant corneal disease.

- Active or prior documented autoimmune or inflammatory disorders.

- Prior exposure to any treatment including ADC containing a chemotherapeutic agent
targeting topoisomerase I and TROP2-targeted therapy.

- Any concurrent anti-cancer treatment.

- Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors or
Dato-DXd.

- Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning
to become pregnant.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/11/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
23/04/2029
Actual
Sample size
Target
625
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Camperdown
Recruitment hospital [2] 0 0
Research Site - Darlinghurst
Recruitment hospital [3] 0 0
Research Site - Heidelberg
Recruitment hospital [4] 0 0
Research Site - Melbourne
Recruitment hospital [5] 0 0
Research Site - Nedlands
Recruitment hospital [6] 0 0
Research Site - Waratah
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
3000 - Melbourne
Recruitment postcode(s) [5] 0 0
6009 - Nedlands
Recruitment postcode(s) [6] 0 0
2298 - Waratah
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Hawaii
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Iowa
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Minnesota
Country [18] 0 0
United States of America
State/province [18] 0 0
Mississippi
Country [19] 0 0
United States of America
State/province [19] 0 0
Missouri
Country [20] 0 0
United States of America
State/province [20] 0 0
New Mexico
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Pennsylvania
Country [24] 0 0
United States of America
State/province [24] 0 0
Rhode Island
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
Washington
Country [29] 0 0
United States of America
State/province [29] 0 0
Wisconsin
Country [30] 0 0
Argentina
State/province [30] 0 0
Buenos Aires
Country [31] 0 0
Argentina
State/province [31] 0 0
Caba
Country [32] 0 0
Argentina
State/province [32] 0 0
Ciudad Autonoma Bs As
Country [33] 0 0
Argentina
State/province [33] 0 0
Rosario
Country [34] 0 0
Argentina
State/province [34] 0 0
San Nicolas de Los Arroyos
Country [35] 0 0
Brazil
State/province [35] 0 0
Barretos
Country [36] 0 0
Brazil
State/province [36] 0 0
Curitiba
Country [37] 0 0
Brazil
State/province [37] 0 0
Florianópolis
Country [38] 0 0
Brazil
State/province [38] 0 0
Goiânia
Country [39] 0 0
Brazil
State/province [39] 0 0
Itajai
Country [40] 0 0
Brazil
State/province [40] 0 0
Porto Alegre
Country [41] 0 0
Brazil
State/province [41] 0 0
Recife
Country [42] 0 0
Brazil
State/province [42] 0 0
Sao Paulo
Country [43] 0 0
Brazil
State/province [43] 0 0
São Paulo
Country [44] 0 0
Brazil
State/province [44] 0 0
Teresina
Country [45] 0 0
Canada
State/province [45] 0 0
Ontario
Country [46] 0 0
Canada
State/province [46] 0 0
Quebec
Country [47] 0 0
Canada
State/province [47] 0 0
Saskatchewan
Country [48] 0 0
China
State/province [48] 0 0
Beijing
Country [49] 0 0
China
State/province [49] 0 0
Bengbu
Country [50] 0 0
China
State/province [50] 0 0
Changchun
Country [51] 0 0
China
State/province [51] 0 0
Changsha
Country [52] 0 0
China
State/province [52] 0 0
Chengdu
Country [53] 0 0
China
State/province [53] 0 0
Chongqing
Country [54] 0 0
China
State/province [54] 0 0
Fuzhou
Country [55] 0 0
China
State/province [55] 0 0
Guangzhou
Country [56] 0 0
China
State/province [56] 0 0
Hangzhou
Country [57] 0 0
China
State/province [57] 0 0
Harbin
Country [58] 0 0
China
State/province [58] 0 0
Hefei
Country [59] 0 0
China
State/province [59] 0 0
Ji Nan
Country [60] 0 0
China
State/province [60] 0 0
Nanchang
Country [61] 0 0
China
State/province [61] 0 0
Nanjing
Country [62] 0 0
China
State/province [62] 0 0
Nanning
Country [63] 0 0
China
State/province [63] 0 0
Shandong
Country [64] 0 0
China
State/province [64] 0 0
Shanghai
Country [65] 0 0
China
State/province [65] 0 0
Shenyang
Country [66] 0 0
China
State/province [66] 0 0
Tianjin
Country [67] 0 0
China
State/province [67] 0 0
Wenzhou
Country [68] 0 0
China
State/province [68] 0 0
Wuhan
Country [69] 0 0
China
State/province [69] 0 0
Xi'an
Country [70] 0 0
China
State/province [70] 0 0
Xiamen
Country [71] 0 0
China
State/province [71] 0 0
Xintai
Country [72] 0 0
China
State/province [72] 0 0
Xuzhou
Country [73] 0 0
China
State/province [73] 0 0
Zhengzhou
Country [74] 0 0
France
State/province [74] 0 0
Lille
Country [75] 0 0
France
State/province [75] 0 0
Lyon
Country [76] 0 0
France
State/province [76] 0 0
Paris
Country [77] 0 0
France
State/province [77] 0 0
Saint Herblain Cedex
Country [78] 0 0
France
State/province [78] 0 0
Toulouse Cedex 9
Country [79] 0 0
Germany
State/province [79] 0 0
Düsseldorf
Country [80] 0 0
Germany
State/province [80] 0 0
Essen
Country [81] 0 0
Germany
State/province [81] 0 0
Georgsmarienhütte
Country [82] 0 0
Germany
State/province [82] 0 0
Hamburg
Country [83] 0 0
Germany
State/province [83] 0 0
Hannover
Country [84] 0 0
Germany
State/province [84] 0 0
Heidelberg
Country [85] 0 0
Germany
State/province [85] 0 0
Heilbronn
Country [86] 0 0
Germany
State/province [86] 0 0
Leipzig
Country [87] 0 0
India
State/province [87] 0 0
Calicut
Country [88] 0 0
India
State/province [88] 0 0
Kochi
Country [89] 0 0
India
State/province [89] 0 0
Kolkata
Country [90] 0 0
India
State/province [90] 0 0
Marg Jaipur
Country [91] 0 0
India
State/province [91] 0 0
Mohali
Country [92] 0 0
India
State/province [92] 0 0
Mysuru
Country [93] 0 0
India
State/province [93] 0 0
Nagpur
Country [94] 0 0
India
State/province [94] 0 0
Nashik
Country [95] 0 0
India
State/province [95] 0 0
New Delhi
Country [96] 0 0
India
State/province [96] 0 0
Pondicherry
Country [97] 0 0
India
State/province [97] 0 0
Surat
Country [98] 0 0
India
State/province [98] 0 0
Vadodara
Country [99] 0 0
India
State/province [99] 0 0
Vishakapatnam
Country [100] 0 0
Italy
State/province [100] 0 0
Empoli
Country [101] 0 0
Italy
State/province [101] 0 0
Milan
Country [102] 0 0
Italy
State/province [102] 0 0
Modena
Country [103] 0 0
Italy
State/province [103] 0 0
Napoli
Country [104] 0 0
Italy
State/province [104] 0 0
Padova
Country [105] 0 0
Italy
State/province [105] 0 0
Roma
Country [106] 0 0
Italy
State/province [106] 0 0
Rozzano
Country [107] 0 0
Japan
State/province [107] 0 0
Akashi-shi
Country [108] 0 0
Japan
State/province [108] 0 0
Bunkyo-ku
Country [109] 0 0
Japan
State/province [109] 0 0
Chiba-shi
Country [110] 0 0
Japan
State/province [110] 0 0
Chuo-ku
Country [111] 0 0
Japan
State/province [111] 0 0
Fukuoka-shi
Country [112] 0 0
Japan
State/province [112] 0 0
Fukushima-shi
Country [113] 0 0
Japan
State/province [113] 0 0
Gifu-shi
Country [114] 0 0
Japan
State/province [114] 0 0
Hidaka-shi
Country [115] 0 0
Japan
State/province [115] 0 0
Hiroshima-shi
Country [116] 0 0
Japan
State/province [116] 0 0
Isehara-shi
Country [117] 0 0
Japan
State/province [117] 0 0
Kamogawa-shi
Country [118] 0 0
Japan
State/province [118] 0 0
Kashiwa
Country [119] 0 0
Japan
State/province [119] 0 0
Kitaadachi-gun
Country [120] 0 0
Japan
State/province [120] 0 0
Koto-ku
Country [121] 0 0
Japan
State/province [121] 0 0
Kumamoto-shi
Country [122] 0 0
Japan
State/province [122] 0 0
Kurume-shi
Country [123] 0 0
Japan
State/province [123] 0 0
Matsuyama-shi
Country [124] 0 0
Japan
State/province [124] 0 0
Nagoya-shi
Country [125] 0 0
Japan
State/province [125] 0 0
Niigata-shi
Country [126] 0 0
Japan
State/province [126] 0 0
Nishinomiya-shi
Country [127] 0 0
Japan
State/province [127] 0 0
Okayama-shi
Country [128] 0 0
Japan
State/province [128] 0 0
Osaka-shi
Country [129] 0 0
Japan
State/province [129] 0 0
Osakasayama-shi
Country [130] 0 0
Japan
State/province [130] 0 0
Ota-shi
Country [131] 0 0
Japan
State/province [131] 0 0
Sapporo-shi
Country [132] 0 0
Japan
State/province [132] 0 0
Sendai-shi
Country [133] 0 0
Japan
State/province [133] 0 0
Shinagawa-ku
Country [134] 0 0
Japan
State/province [134] 0 0
Shinjuku-ku
Country [135] 0 0
Japan
State/province [135] 0 0
Tsu-shi
Country [136] 0 0
Japan
State/province [136] 0 0
Tsukuba
Country [137] 0 0
Japan
State/province [137] 0 0
Yokohama-shi
Country [138] 0 0
Korea, Republic of
State/province [138] 0 0
Busan
Country [139] 0 0
Korea, Republic of
State/province [139] 0 0
Daegu
Country [140] 0 0
Korea, Republic of
State/province [140] 0 0
Goyang-si
Country [141] 0 0
Korea, Republic of
State/province [141] 0 0
Seoul
Country [142] 0 0
Mexico
State/province [142] 0 0
CD Mexico
Country [143] 0 0
Mexico
State/province [143] 0 0
Guadalajara
Country [144] 0 0
Mexico
State/province [144] 0 0
Mexico City
Country [145] 0 0
Mexico
State/province [145] 0 0
Mexico
Country [146] 0 0
Mexico
State/province [146] 0 0
México
Country [147] 0 0
Mexico
State/province [147] 0 0
Tuxtla Gutierrez
Country [148] 0 0
Philippines
State/province [148] 0 0
Bacolod
Country [149] 0 0
Philippines
State/province [149] 0 0
Cebu City
Country [150] 0 0
Philippines
State/province [150] 0 0
Manila
Country [151] 0 0
Philippines
State/province [151] 0 0
Muntinlupa City
Country [152] 0 0
Philippines
State/province [152] 0 0
Quezon City
Country [153] 0 0
Philippines
State/province [153] 0 0
San Juan
Country [154] 0 0
Poland
State/province [154] 0 0
Bialystok
Country [155] 0 0
Poland
State/province [155] 0 0
Bydgoszcz
Country [156] 0 0
Poland
State/province [156] 0 0
Gdansk
Country [157] 0 0
Poland
State/province [157] 0 0
Gdynia
Country [158] 0 0
Poland
State/province [158] 0 0
Konin
Country [159] 0 0
Poland
State/province [159] 0 0
Kraków
Country [160] 0 0
Poland
State/province [160] 0 0
Legnica
Country [161] 0 0
Poland
State/province [161] 0 0
Lublin
Country [162] 0 0
Poland
State/province [162] 0 0
Przemysl
Country [163] 0 0
Poland
State/province [163] 0 0
Warszawa
Country [164] 0 0
Poland
State/province [164] 0 0
Wroclaw
Country [165] 0 0
Poland
State/province [165] 0 0
Lódz
Country [166] 0 0
Singapore
State/province [166] 0 0
Singapore
Country [167] 0 0
South Africa
State/province [167] 0 0
Cape Town
Country [168] 0 0
South Africa
State/province [168] 0 0
Johannesburg
Country [169] 0 0
South Africa
State/province [169] 0 0
Pretoria
Country [170] 0 0
Spain
State/province [170] 0 0
Barcelona
Country [171] 0 0
Spain
State/province [171] 0 0
Granada
Country [172] 0 0
Spain
State/province [172] 0 0
Hospitalet deLlobregat
Country [173] 0 0
Spain
State/province [173] 0 0
Madrid
Country [174] 0 0
Spain
State/province [174] 0 0
Pamplona
Country [175] 0 0
Spain
State/province [175] 0 0
Santander
Country [176] 0 0
Taiwan
State/province [176] 0 0
Hsinchu
Country [177] 0 0
Taiwan
State/province [177] 0 0
Kaohsiung
Country [178] 0 0
Taiwan
State/province [178] 0 0
Taichung
Country [179] 0 0
Taiwan
State/province [179] 0 0
Tainan
Country [180] 0 0
Taiwan
State/province [180] 0 0
Taipei
Country [181] 0 0
Taiwan
State/province [181] 0 0
Taoyuan
Country [182] 0 0
Thailand
State/province [182] 0 0
Bangkok
Country [183] 0 0
Thailand
State/province [183] 0 0
Chiang Mai
Country [184] 0 0
Thailand
State/province [184] 0 0
Dusit
Country [185] 0 0
Thailand
State/province [185] 0 0
Khon Kaen
Country [186] 0 0
Thailand
State/province [186] 0 0
Songkhla
Country [187] 0 0
Turkey
State/province [187] 0 0
Ankara
Country [188] 0 0
Turkey
State/province [188] 0 0
Besevler Ankara
Country [189] 0 0
Turkey
State/province [189] 0 0
Izmir
Country [190] 0 0
Turkey
State/province [190] 0 0
Küçükçekmece
Country [191] 0 0
Turkey
State/province [191] 0 0
Samsun
Country [192] 0 0
United Kingdom
State/province [192] 0 0
Cardiff
Country [193] 0 0
United Kingdom
State/province [193] 0 0
Chelsea
Country [194] 0 0
United Kingdom
State/province [194] 0 0
Leicester
Country [195] 0 0
United Kingdom
State/province [195] 0 0
Liverpool
Country [196] 0 0
United Kingdom
State/province [196] 0 0
London
Country [197] 0 0
United Kingdom
State/province [197] 0 0
Oxford
Country [198] 0 0
United Kingdom
State/province [198] 0 0
Surrey
Country [199] 0 0
United Kingdom
State/province [199] 0 0
Sutton
Country [200] 0 0
Vietnam
State/province [200] 0 0
Hanoi
Country [201] 0 0
Vietnam
State/province [201] 0 0
Ho Chi Minh City
Country [202] 0 0
Vietnam
State/province [202] 0 0
Vinh

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Daiichi Sankyo
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study
assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with
investigator's choice chemotherapy in combination with pembrolizumab in participants with
PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06103864
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
information.center@astrazeneca.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06103864